Discusión

Titulo

Comunicación Nº: 089

Expresión de p53 en el carcinoma ductal infiltrante de mama. Correlación con factores pronósticos.

Aranda FI, Laforga JB, Gil-Hervas P, Chulia MT.

Servicio de Anatomía Patológica. Hospital General Universitario de Alicante. España.

[Título] [Introducción] [Material y Métodos] [Resultados] [Iconografía] [Discusión]

BIBLIOGRAFÍA

  1. Aranda FI, Laforga JB. Microvessel quantitation in breast ductal invasive carcinoma: correlation with proliferative activity, hormonal receptors and lymph node metastases. Pathol Res Pract 1996; 92: 124-9.
  2. Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma PD. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with recpetor status, proliferation markeres, and clinical stage in human breast cancer. Am J Clin Pathol 1992; 98: 408-418.
  3. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 1993; 24:469-476.
  4. Bosari S, Lee AKC, DeLellis RA, Wiley BD, Heartly GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992; 23: 755-61
  5. Cattoretti G, Rilke F, Andreola S, S’Amato L, Delia D. p53 expression in breast cancer. Int J Cancer 1988; 41: 178-83.
  6. Ceccarelli C, Santini D, Chieco P, Taffurelli M, Marrano D, Mancini AM. Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: a useful tool for elucidating its biological behaviour. Ann Oncol 1995; 6: 275-82.
  7. Charpin C, Devictor B, Bergeret D, Andrac L, Boulat J, Horschowski N, Lavaut MN, Piana L. CD31 quantitative immunocytochemical assays in breast carcinomas. Correlation with current prognostic factors. J Clin Pathol Med 1995; 103: 443-8.
  8. Dabbs DJ. Correlations of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating cell nuclear antigen, p53, epidermal growth factor receptor, and c-erb-b-2. Modern Pathol 1995; 8: 637-42.
  9. Dameron KM, et al. Control of angiogenesis in fibroblastos by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
  10. Davidoff AM, Herndon JE, Glover NS, Kerns BJM, Pence JC, Iglehart JD, Marks JR. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 1991; 110: 259-64.
  11. Deng G, Chen LC, Schott DR, Thor A, Bhargava V, Ljung BM, Chew K, and Smith HS. Loss of heterozygosity and p53 gene mutations in breast cancer. Cancer Research, 1994; 54: 499-505.
  12. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
  13. Eriksson ET, Schimmelpenning H, Aspenblad U, Zetternerg A, Auer GU. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. Hum Pathol 1994; 25: 1228-33.
  14. Friedrich K, Dimmer V, Haroske G, Lob nitzer A, Ksaper M, Theissing F, Kunze KD. Expression of p53 and bcl-2 in correlation to clinicopathological parameters, hormone receptor status and DNA ploidy in breast cancers. Path Res Pract 1995; 191: 1114-1121
  15. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Palma PD, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994; 12: 454-66.
  16. Haerslev T, Jacobsen GK. An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. Hum Pathol 1995; 26: 295-301.
  17. Hall PA, Meek D, Lane DP. P53. Integrating the complexity (editorial). J Pathol 1996; 180: 1-5.
  18. Hollstein M, Sidranski D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253:49,1991
  19. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL: Angiogenesis assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120-1124.
  20. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S. Nuclear p43 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Ras 1991; 82: 835-40.
  21. Levine AJ, Momand J, Finlay CA. He p53 tumor supressor gene. Nature 1991; 351: 453-6.
  22. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr, Nelson CE, Kim DH, Kassel J Gryka MA, Bischoff FZ, Tainski MA: Germ line p53 mutations in a familiar syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233,1990
  23. Marks JR, Humphrey PA, Wu K, Berry D, Bandarenko N, Kerns B-J M, Iglehart JD. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994; 219: 332-41.
  24. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S. Relationship between p53 expression and other prognostic factor in human breast carcinoma. An immunohistochemical study. Am J Clin Pathol 1993; 100: 213-7
  25. Mazars R, Spinardi L, BenCheikh M, Lafontaina J, Jeanteur P, Theillet C. p53 mutations occur in aggresive breast cancer. Cancer Res 1992; 52:3918-3923.
  26. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985; 109:716-21.
  27. Moriki T, Takahashi T, Tanioka F, Yamane T, Hara H. Proliferative activity in breast carcinoma evaluated by BrdU and PCNA. Correlation with expression of p53, c-erbB-2, estrogen receptro and P-glycoprotein. Path Res Pract 1995; 191: 1122-1132.
  28. Nakopoulou LL, Alexiadou A, Theodoropulos GE, Lazaris AC, Tzonou A, Keramopoulos A. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. J Pathol 1996; 179:21-8.
  29. Ostrowski JL, Sawan A, Henry L, et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 1991; 164: 75-81.
  30. Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma V-M, Syrjänen K. Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 1995; 177: 225-32.
  31. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 1993; 24: 463-468.
  32. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma: an immunohistochemcial study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995; 13: 821-30.
  33. Sawan A, Randall B, Angus B, et al. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol 1992; 168: 23-28.
  34. Shaw PH. The role of p53 in cell cycle regulation. Path Res Pract 1996; 192: 669-75.
  35. Sheikh MS, Shao ZM, Hussain A, et al. The p53 binding protein mdm-2 gene is differentially expressed in human breast carcinomas. Cancer Res 1993; 53: 3226-8.
  36. Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clinical Chemistry 1996; 42:858-68.
  37. Visscher DW, Sarkar FH, Wykes S, Kothari K, Macoska J, Crissman J. Clinicopatholic significance of p53 immunostaining in adenocarinoma of the breast. Arch Pathol Lab Med 2993; 117: 973-6.
  38. Walker RA, Dearing SJ, Lane DP, Varley JM. Expression of p53 protein in infiltrating and in situ breast carcinomas. J Pathol 1991; 165: 203-11.
  39. Weidner N, Semple JP, Welch WR, Folkman J. N Tumor angiogenesis and metastasis. Correlaction in invasive breast carcinoma. Engl J Med. 1991; 324: 2-8
  40. Wynford-Thomas D. p53 in tumour pathology: can we trust immunocytochemistry? (Editorial). J Pathol 1992; 166: 329-330.

Discusión

Titulo